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tween high levels of serum phosphate and FGF23 and car-
diovascular morbidity and mortality. Yet, so far, no inter-
vention has been shown to simultaneously restore calci-
um/phosphate metabolism and improve cardiovascular 
prognosis. Furthermore, although it is plausible to as-
sume that deregulated calcium/phosphate metabolism 
contributes to media calcification, its potential role in 
atherosclerotic plaque formation is less clearly defined. In 
atherosclerosis additional processes, including the activa-
tion of pro-inflammatory pathways, may instead play a 
more prominent role.
 The complement system is an important component 
of innate immunity that primarily functions as a host de-
fense against pathogenic infections. Uncontrolled activa-
tion of the complement system can result in renal and 
systemic diseases including atypical hemolytic uremic 
syndrome (aHUS)  [7] and membranoproliferative glo-
merulonephritis  [8] . Furthermore, deregulations in the 
complement system have also been linked with endothe-
lial dysfunction, atherosclerosis, and impaired coagula-
tion  [9] . Of interest, several studies in non-renal patients 
have shown associations between complement compo-
nents and cardiovascular disease. Particularly a higher 
circulating level of C3, which plays a central role in the 
activation of the complement pathway ( fig. 1 ), has been 
 Cardiovascular disease is by far the leading cause of 
death in patients with end-stage renal disease (ESRD), 
comprising more than half of all known causes of death 
 [1] . Arteriosclerosis, characterized by medial calcification 
and sclerosis, and atherosclerosis, characterized by lipid 
plaque formation, are 2 distinct processes that play a ma-
jor role in the etiology of cardiovascular disease in ESRD. 
It is incompletely understood which factors drive the ac-
celerated arteriosclerosis and atherosclerosis observed in 
advanced chronic kidney disease.
 Arteriosclerosis is characterized by progressive calcifi-
cation of the arterial tunica media. Vascular calcification 
is already abundantly present in adolescent patients with 
ESRD  [2] , and it is therefore not surprising that cardio-
vascular disease is the main cause of death even in chil-
dren and young adults with ESRD  [3] . The development 
and progression of vascular calcifications, and subse-
quent dismal clinical outcomes  [4] , is accompanied by 
profound deregulations in calcium/phosphate metabo-
lism in many ESRD patients. Consequently, the involve-
ment of serum phosphate and its regulating hormone fi-
broblast growth factor 23 (FGF23) as potential risk fac-
tors for adverse cardiovascular outcomes in ESRD has 
been extensively studied over the past decade  [5, 6] . These 
studies have consistently demonstrated associations be-
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linked with insulin resistance and incident diabetes  [10, 
11] , disturbed lipid metabolism  [12] , and incident and 
prevalent coronary heart disease  [13, 14] . Besides C3, 
higher circulating levels of mannose-binding lectin have 
also been associated with incident coronary artery disease 
 [15] , whereas factor D (also known as adipsin) and C4 
have been linked with the development of stroke  [16, 17] . 
More downstream, the role of C5b-9, comprising the 
membrane attack complex (MAC), has been implicated 
in atherosclerotic plaque formation in preclinical studies 
 [18] , and its soluble form has been associated with all-
cause mortality and major cardiovascular events in pa-
tients with myocardial infarction  [19] . Similarly, the 
downstream component C5a has been associated with 
cardiovascular disease in patients with advanced athero-
sclerosis  [20] . Although these data come from a limited 
number of studies performed in generally small cohorts, 
and reported data have not always been consistent  [9] , 
these findings do warrant further investigation of the role 
of the complement system in patients with advanced 
chronic kidney disease.
 In this issue of  Nephron , Lines et al.  [21] link activation 
of the complement system with an increased risk of car-
diovascular events in hemodialysis patients. The authors 
performed a post-hoc analysis of a clinical trial in which 
260 hemodialysis patients were randomized to dialysis 
with a vitamin E-coated dialysis membrane or a non-vi-
tamin E-coated equivalent. The type of dialysis mem-
brane did not modify mortality at one year after initiation 
of the trial, nor did this affect circulating levels of the 
complement components C3, factor D, factor H, or solu-
ble C5b-9. However, when assessing complement com-
ponents measured at baseline, the authors found that a 
higher baseline C3 level was associated with a higher risk 
of subsequent cardiovascular events. Given the relatively 
small sample size and limited number of patients devel-
oping a cardiovascular event (n = 33), the authors could 
not adjust for potential confounders. Thus, this pioneer-
 Fig. 1. The complement system and cardiovascular risk. Overview 
of the main components of the complement system, and its asso-
ciations with cardiovascular disease and its risk factors. The com-
plement system consists of the classical pathway, the lectin path-
way, and the alternative pathway, all of which converge on the 
C3-mediated generation of C5b-9, the MAC, C3a-5a, and C3b. 
Associations with cardiovascular disease and/or risk factors are 
indicated in dotted lines, and smaller font sizes reflect weak evi-
dence (limited studies and/or sample size). MASP  = Mannose-





































































ing study should be followed up by larger and more ex-
tensively adjusted analyses in order to substantiate this 
observation. Interestingly, when additionally studying 
the relationship between C5b-9 and cardiovascular 
events, the authors found that both a high and a low level 
of C5b-9 was associated with a higher cardiovascular risk 
in hemodialysis patients. Further studies are needed to 
understand the implications of this observation, which 
can at least partly be reconciled with previous data  [19] .
 Which mechanisms could connect complement acti-
vation and the increased risk of cardiovascular disease in 
hemodialysis patients? First, complement activation may 
induce a pro-inflammatory state in the vascular wall, pro-
moting atherosclerotic plaque formation and destabiliza-
tion. Second, cardiovascular fat serves as a source of C3, 
and hence C3 could be merely a marker of prevalent ath-
erosclerosis  [22] . This further supports the need for anal-
yses adjusted for markers and/or risk factors of prevalent 
atherosclerosis such as obesity, diabetes and hyperten-
sion. A third possibility, also raised by Lines et al.  [21] , is 
that complement activation could well be induced by di-
alysis treatment in itself, for instance, due to the use of 
bioincompatible materials including the dialysis mem-
brane  [23] . It is well established that hemodialysis in itself 
inflicts cardiovascular stress, which could be mediated by 
hemodynamic effects  [24] , but also by a pro-inflammato-
ry profile of patients prone to experience hemodialysis-
induced cardiac stress  [25] . This pro-inflammatory state 
may, in turn, be related to dialysis (membrane)-induced 
complement activation in this category of patients. Un-
fortunately, the vitamin E-coated membranes used in the 
active treatment arm of the trial reported by Lines et al. 
 [21] affected neither complement activation (although 
the effect on more specific markers such as C3d could not 
be assessed in this study) nor clinical outcomes  [21] . On 
the other hand, the authors also observed declining C3 
levels over time in both study arms (p-trend <0.0001), 
which would render a main role for hemodialysis treat-
ment as a cause of complement activation less likely.
 Should the complement system be considered a novel 
therapeutic target to improve cardiovascular outcomes in 
hemodialysis patients? The therapeutic potential of inter-
ventions targeting the complement system to modify car-
diovascular risk in diabetic patients was recently high-
lighted by the identification of a novel peptide that abol-
ished C3-induced prolongation of fibrin clot lysis, by 
interfering with the interaction between C3 and fibrino-
gen  [26] . This peptide could provide a novel therapy tar-
geting thrombosis in patients with diabetes. The comple-
ment C5 inhibitor eculizumab has shown beneficial ef-
fects not only in patients with aHUS, but also in some (but 
not all) patients with dense-deposit disease  [27] . Impor-
tantly, a recent study also showed reduction of inflamma-
tion, endothelial damage and thrombosis by eculizumab 
in patients with aHUS  [28] , but whether such effects 
could also be observed in ESRD patients without hemo-
lytic uremic syndrome is unclear. Given the high costs of 
eculizumab, its potential application to reduce the exces-
sive cardiovascular risk in the hemodialysis population 
seems currently one bridge too far. Meanwhile, it may be 
worthwhile to further document the relationship between 
complement components and cardiovascular outcomes 
in well-adjusted analyses in larger cohorts, and to study 
the cardiovascular protective effects of interventions tar-
geting complement activation, including eculizumab, in 
selected patient groups.
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